Fractyl Logo
Large Intestine

PIONEERING BREAKTHROUGH THERAPIES TO TREAT TYPE 2 DIABETES (T2D) AND OBESITY

Our vision is to develop transformative therapies that have the potential to prevent and eliminate metabolic diseases. We are a mission-driven team of innovators, singularly focused on developing therapies that are designed to target root causes of T2D and obesity and delivering those therapies to patients as broadly and rapidly as possible.

Duodenal Nutrient Sensing and Signaling
Duodenal Nutrient Sensing and Signaling
Duodenal Nutrient Sensing and Signaling
Duodenal Nutrient Sensing and Signaling

REVITA®

Revita is an outpatient procedural therapy designed to durably modify duodenal dysfunction via hydrothermal ablation in order to restore metabolic health.

Learn About Revita

SEEKING A MAJOR ADVANCE IN GLP-1 MEDICINES WITH PANCREATIC GENE THERAPY

Rejuva is a novel, locally administered, AAV gene therapy platform currently in preclinical development to improve islet function. We believe the platform represents a major advance in incretin-based therapies. PGTx is designed to potentially enable long-term remission of T2D and obesity by durably altering metabolic hormone response in the pancreatic islet cells of patients with those diseases.

Learn about Rejuva
AAV-delivered glucagon-like peptide 1 receptor agonist (GLP1RA) gene therapy
AAV-delivered glucagon-like peptide 1 receptor agonist (GLP1RA) gene therapy